The triad in current neuroblastoma challenges: Targeting antigens, enhancing effective cytotoxicity and accurate 3D...

Area of Science:

• Pediatric Oncology
• Cancer Immunology
• Translational Medicine

Background:

• Neuroblastoma, a pediatric cancer from neural crest cells, causes significant mortality, with high-risk patients often relapsing.
• Current therapies are insufficient, necessitating novel precision medicine approaches like immunotherapy.
• Developing effective neuroblastoma immunotherapies is hindered by the immunosuppressive tumor microenvironment and low mutational burden.

Purpose of the Study:

• To review current and emerging strategies for neuroblastoma immunotherapy.
• To discuss the challenges and potential solutions in developing effective immunotherapeutic approaches.
• To highlight the importance of innovative research methodologies in advancing neuroblastoma treatment.

Main Methods:

• Review of literature on neuroblastoma immunotherapy, focusing on antigen discovery, immunomodulation, and in vitro models.
• Examination of the tumor-immune microenvironment in neuroblastoma.
• Discussion of the utility of 3D in vitro tumor models as alternatives to animal studies.

Main Results:

• Identification of key challenges in neuroblastoma immunotherapy, including the immunosuppressive tumor microenvironment.
• Exploration of tumor antigen discovery and immunomodulation as therapeutic avenues.
• Emphasis on the potential of advanced 3D in vitro models to accelerate immunotherapy development.

Conclusions:

• Innovative approaches combining antigen discovery, immunomodulation, and advanced in vitro models are crucial for overcoming neuroblastoma immunotherapy challenges.
• Physiologically relevant in vitro systems can expedite the testing of novel immunotherapies.
• Improving patient survival and long-term outcomes requires comprehensive and effective immunotherapy strategies for neuroblastoma.